# Study of ZGGS18 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05584800/  
OnCo record `nct05584800` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ZGGS18 for Injection in advanced solid tumours, run by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, now recruiting.

## Summary

Study of ZGGS18 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05584800 by Suzhou Zelgen Biopharmaceuticals Co.,Ltd, with 222 participants planned, started 2022-11-15 and due to reach its primary completion in 2026-11-01. Interventions recorded: ZGGS18 for Injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05584800
- Phase: 1/2
- Setting: A Phase I/II Dose Escalation, Tolerability, Safety, Pharmacokinetics and Multiple Cohort Expansion Study of ZGGS18 in Patients With Advanced Solid Tumors
- Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Enrolled: 222

## Sources

- ClinicalTrials.gov NCT05584800: https://clinicaltrials.gov/study/NCT05584800

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Suzhou Zelgen Biopharmaceuticals](https://onco.cc/companies/zelgen/)

---
JSON: https://onco.cc/api/v1/entities/nct05584800.json